The pharmaceutical landscape has been fundamentally reshaped by the rapid ascent of glucagon-like peptide-1 (GLP-1) receptor agonists. What began nearly a decade ago as a targeted therapy for glycemic control in type 2 diabetes has evolved into a pharmacological juggernaut, with applications spanning obesity, cardiovascular disease, obstructive sleep apnea, chronic kidney disease, and most recently, metabolic dysfunction-associated steatohepatitis (MASH).
As these drugs permeate nearly every facet of metabolic and systemic health, they have triggered a massive downstream effect on the life sciences infrastructure. Specifically, the gold rush for GLP-1 innovation has rendered legacy biospecimen collections insufficient, forcing researchers and biobanks to pivot toward more complex, highly annotated, and diverse biological samples.
A Decade of Rapid Expansion: A Chronology of the GLP-1 Era
The speed at which the GLP-1 class has matured is unprecedented in modern drug development.
- 2017: The FDA approves semaglutide (Ozempic) for the management of type 2 diabetes, marking the birth of the modern era of incretin mimetics.
- 2021: With the approval of semaglutide (Wegovy) for chronic weight management, the drug class transitions from a metabolic stabilizer to a lifestyle-altering blockbuster.
- 2022–2023: The market sees the introduction of "dual-action" therapies with the approval of tirzepatide (Mounjaro for diabetes, Zepbound for obesity), which targets both GIP and GLP-1 receptors.
- 2024: The scope of clinical utility widens significantly. In March, Wegovy is cleared for reducing cardiovascular risk in obese patients. By December, Zepbound secures the first-ever approval for the treatment of obstructive sleep apnea.
- 2025: The therapeutic horizon expands further into organ-specific damage. Ozempic gains approval for slowing chronic kidney disease progression. In August, Wegovy becomes the first GLP-1 approved for MASH with moderate-to-advanced fibrosis. By December, the first oral GLP-1 pill reaches the market.
- 2026: In April, the FDA approves orforglipron (Foundayo), the first oral small-molecule GLP-1, following the fastest new-drug clearance process seen since 2002.
The Shifting Requirements of Research and Development
This rapid expansion has created a structural disconnect between existing biospecimen inventories and the requirements of current R&D pipelines. Biobanks that were built during the "weight-loss-only" era primarily collected samples aimed at measuring basic metabolic endpoints. However, as researchers pivot toward investigating the role of these drugs in neurodegeneration, oncology, and liver fibrosis, those original samples—and the data associated with them—often lack the granularity needed for modern, high-stakes investigations.
"If you think about what GLP-1s were first developed for, a lot of it was around weight loss," explains Cathie Miller, Ph.D., director of product management operations at BioIVT. "As the science has evolved, those original samples the biobanks collected are no longer as relevant. They don’t contain the tumor samples, the specific neurological markers, or the high-fidelity liver tissue now required to understand these new disease pathways."
The Pivot Toward Biofluids
Perhaps the most significant change in the industry is the shift from solid tissue reliance to a more sophisticated use of biofluids. While surgical resections of oncology tissue were once the gold standard, the move toward systemic, chronic disease management has made the use of liquid biopsies and non-invasive biofluids essential.
"Ten years ago, it was predominantly tissue," Miller notes. "Now, we are seeing a drive toward biofluids—not just blood-derived plasma or serum, but urine, feces, and saliva." This shift is reflected in the internal business metrics at organizations like BioIVT, where the historical 60/40 split between tissue and biofluids has effectively inverted to 60/40 in favor of biofluids. This trend is bolstered by advancements in exosome research and liquid biopsy technology, which allow researchers to extract granular disease insights from non-invasive samples.
Implications: The High Cost of Access and Innovation
The economic realities of the GLP-1 class are as transformative as the biological ones. As of July 1, 2026, Medicare has begun covering these agents for weight loss, significantly increasing the accessibility of these drugs for the elderly population. Yet, the supply chain for the drugs themselves is only half the story; the supply chain for the research tools needed to study them is equally critical.
Market researchers have valued the global biospecimen procurement market at approximately $5 billion as of 2024, with expectations of it climbing past $11 billion by 2033. Despite this growth, there remains a bottleneck: roughly 80% of researchers report having to narrow the scope of their studies due to an inability to source high-quality, well-annotated specimens.
Addressing the MASH Challenge
The approval of Wegovy for MASH has specifically highlighted the need for specialized hepatocyte models. Unlike basic metabolic research, MASH studies require liver tissue that displays specific pathological characteristics—such as fat deposition scores and fibrotic markers.
Brian Ogilvie, Ph.D., vice president of scientific consulting at BioIVT, notes that the industry is no longer satisfied with generic "normal" liver cells. "People are asking, for example, ‘Do you have scores for liver fattiness?’ It may be difficult to get a true, definitive pathological confirmation of MASH from all donors, but sponsors are looking for any indication of those characteristics to drive their ADME (Absorption, Distribution, Metabolism, and Excretion) studies," Ogilvie says. This demand has spurred the development of advanced in vitro platforms like HEPATOPAC, which are designed to support chronic, long-term liver modeling that was previously impossible.
The Frontier: Neurology and Oncology
Perhaps the most ambitious frontier for GLP-1 therapy is the central nervous system. While headline-grabbing trials, such as the EVOKE and EVOKE+ trials for Alzheimer’s and the Exenatide-PD3 trial for Parkinson’s, have yielded mixed or disappointing clinical outcomes, the scientific community remains undeterred.
Because brain tissue is largely inaccessible in living patients, the demand for cerebrospinal fluid (CSF) has surged. Researchers are using this fluid to track biomarkers, hoping to understand the mechanisms of neurodegeneration even in cases where clinical outcomes have yet to show a slowing of disease progression.
Similarly, in oncology, there is a growing, albeit observational, signal that GLP-1 usage may be linked to lower incidences of certain obesity-related cancers, including breast, colorectal, and pancreatic cancer. This potential "cancer-protective" effect has created a specialized demand for biobanks to provide tumor samples that are not only high-quality but are also deeply annotated with the donor’s metabolic and pharmaceutical history.
Ensuring Data Integrity: The Role of Annotation
Ultimately, the utility of a biospecimen in the current era is defined by the "wrapper" of clinical data surrounding it. Miller emphasizes that modern biobanking is as much about record-keeping as it is about cold storage.
"If it’s a biobank like ours, we collect as much medical history as the donor will provide," Miller says. "We track current medications, past treatments, and longitudinal outcomes. We want to know: after being on a GLP-1, did the donor develop cancer? Did their kidney function improve? That clinical annotation is where the value lies for the next generation of drug discovery."
As the GLP-1 class continues to evolve, moving from treating symptoms to potentially modifying the course of chronic disease, the demand for "smarter" biospecimens will only intensify. The industry is no longer looking for broad-spectrum samples; it is searching for precision, annotation, and the capability to study disease in the context of a globally medicated, metabolism-shifted population. The success of future therapeutics will depend less on the sheer volume of data, and more on the quality and relevance of the biological samples that serve as the foundation for the next decade of discovery.
About the Author
